Varseta-M Phase 1 Enrollment Complete, Data by Year-End; Q2 Revenue Plunged 92%
CTMX has more than doubled off its 52-week low of $1.72.
Summary
CytomX completed enrollment in the 113-patient Varseta-M Phase 1 CRC monotherapy trial, with data expected by end-2026 and a registrational study planned for 1H-2027. This follows the Q2 2026 financials reported on August 6, where revenue collapsed 92% YoY to $1.42M, missing consensus by 88%, and the net loss widened to $20.7M. The company's cash position of $330.3M extends runway into 2028, providing funding through key clinical readouts. The enrollment milestone de-risks the Varseta-M timeline and sets up a catalyst-rich period ahead.
At the time of this announcement, CTMX was trading at $3.48 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $753.9M. The 52-week trading range was $1.72 to $8.21. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Wiseek News.